Mobile website
Archive > Volume 20 Issue 2 > 2013,20(2):166-171. DOI:10.3872/j.issn.1007-385X.2013.02.006 Prev Next
Basic Research
Ad-ING4 combined with radiotherapy suppresses growth of SPC-A1 cell-transplanted lung adenocarcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To study the anticancer effect of adenovirus-mediated inhibitor of growth family 4 (Ad-ING4) combined with radiotherapy on SPC-A1 transplanted lung adenocarcinoma. Methods: SPC-A1 tumor-bearing mice were established and anticancer experiment was conducted on these mice after being randomly divided into 5 groups: PBS group, Ad group, Ad-ING4 group, radiotherapy group and Ad-ING4 combined with radiotherapy group. Tumor growth was recorded by volume. All tumors were taken out and weighed at 15 days after treatment. The morphology of lung adenocarcinoma SPC-A1 cells was observed by H-E staining. The expressions of Bax, caspase-3, Bcl-2, and VEGF were detected by immunohistochemisty. Results: The tumor volume of the Ad-ING4 combined with radiotherapy group was much smaller than that of the Ad-ING4 group and the single radiotherapy group (\[743.84±109.06\]mm3 vs \[1136.03±151.58\]mm3, \[1035.67±86.27\]mm3, P<0.01). The anticancer rate of the Ad-ING4 combined with radiotherapy group was also much better than that of the Ad-ING4 group and the single radiotherapy group (69.62% vs 33.17% vs 35.41%, P<001), which showed an enhanced radiosensitivity and a synergetic effect (Q=1.22). Immunohistochemistry results showed that Ad-ING4 combined with radiotherapy could obviously up-regulate the expressions of Bax, caspase-3 and down-regulate the expressions of Bcl-2 and VEGF. And the effect of the combined group was better than the single Ad-ING4 or radiotherapy group (P<0.01). Conclusion: Ad-ING4 combined with radiotherapy can effectively inhibit the growth of SPC-A1 cell-transplanted lung adenocarcinoma.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 81001016), and the Medical Research Foundation of Jiangsu Provincial Health Bureau (No．H200914)
Clc Number:
